Immunome (NASDAQ:IMNM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
Several other analysts also recently commented on the company. Wedbush increased their price objective on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Truist Financial increased their price objective on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Finally, Alliance Global Partners initiated coverage on Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 price target for the company. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.18.
Read Our Latest Analysis on Immunome
Immunome Stock Performance
Immunome (NASDAQ:IMNM – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, research analysts forecast that Immunome will post -2.38 EPS for the current year.
Insider Transactions at Immunome
In other Immunome news, Director Isaac Barchas sold 101,050 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the completion of the transaction, the director owned 308,504 shares in the company, valued at $6,515,604.48. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the transaction, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. The trade was a 64.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 580,510 shares of company stock worth $13,824,240 over the last 90 days. 7.21% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of IMNM. Allworth Financial LP bought a new stake in Immunome during the 2nd quarter valued at $25,000. Integrated Wealth Concepts LLC purchased a new position in shares of Immunome in the second quarter valued at $27,000. KBC Group NV purchased a new position in shares of Immunome in the first quarter valued at $60,000. Assetmark Inc. raised its stake in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares during the period. Finally, State of Wyoming bought a new stake in shares of Immunome during the 2nd quarter valued at $109,000. 44.58% of the stock is owned by institutional investors.
Immunome Company Profile
Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.
Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.
Featured Stories
- Five stocks we like better than Immunome
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo.jpg){kind=logo}
